Get the Stockscreener App
105.95
3.28%
3.36
After Hours:
105.95
Rhythm Pharmaceuticals Inc stock is traded at $105.95, with a volume of 496.06K.
It is up +3.28% in the last 24 hours and down -5.52% over the past month.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
See More
Previous Close:
$102.59
Open:
$101.78
24h Volume:
496.06K
Relative Volume:
0.66
Market Cap:
$7.07B
Revenue:
$136.86M
Net Income/Loss:
$-168.69M
P/E Ratio:
-37.70
EPS:
-2.81
Net Cash Flow:
$-113.49M
1W Performance:
-6.52%
1M Performance:
-5.52%
6M Performance:
+19.54%
1Y Performance:
+84.20%
1-Day Range:
$101.78
$106.10
1-Week Range:
$99.10
$114.00
52-Week Range:
$45.91
$122.20
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Name
Rhythm Pharmaceuticals Inc
Sector
Industry
Phone
857-264-4280
Address
222 BERKELEY STREET, BOSTON, MA
Compare RYTM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
105.95 | 6.85B | 136.86M | -168.69M | -113.49M | -2.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.14 | 112.16B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.33 | 77.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
816.37 | 50.10B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
365.46 | 46.97B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
341.64 | 36.99B | 4.98B | 69.59M | 525.67M | 0.5197 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-25-25 | Initiated | Citigroup | Buy |
| Nov-05-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-10-25 | Initiated | Goldman | Buy |
| Jul-07-25 | Initiated | Leerink Partners | Outperform |
| Apr-07-25 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-05-25 | Resumed | Stifel | Buy |
| Jan-02-25 | Initiated | Jefferies | Buy |
| Dec-20-24 | Initiated | Oppenheimer | Outperform |
| Oct-21-24 | Initiated | Guggenheim | Buy |
| Sep-18-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | JMP Securities | Mkt Outperform |
| May-08-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-01-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Aug-08-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-05-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-17-22 | Reiterated | Needham | Buy |
| Mar-02-22 | Resumed | Stifel | Buy |
| Feb-17-22 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-14-21 | Resumed | Goldman | Neutral |
| Aug-04-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Aug-04-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Nov-30-20 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-08-20 | Initiated | Goldman | Sell |
| Jul-12-19 | Upgrade | Stifel | Hold → Buy |
| Jul-08-19 | Initiated | Canaccord Genuity | Buy |
| Mar-13-19 | Initiated | Ladenburg Thalmann | Buy |
| Sep-07-18 | Resumed | Morgan Stanley | Overweight |
| Jun-25-18 | Reiterated | Needham | Buy |
| Jun-15-18 | Reiterated | Needham | Buy |
| Oct-30-17 | Initiated | BofA/Merrill | Buy |
| Oct-30-17 | Initiated | Needham | Buy |
View All
Rhythm Pharmaceuticals Inc Stock (RYTM) Latest News
Zacks Research Downgrades Rhythm Pharmaceuticals (NASDAQ:RYTM) to Strong Sell - MarketBeat
Earnings Miss: Will Rhythm Pharmaceuticals Inc stock go up in YEARTake Profit & Weekly Return Optimization Alerts - baoquankhu1.vn
Rhythm Pharmaceuticals stock price target raised to $125 from $123 at H.C. Wainwright - Investing.com Canada
Breaking Down Rhythm Pharmaceuticals: 13 Analysts Share Their Views - Benzinga
HC Wainwright & Co. Reaffirms Buy Rating for RYTM with Increased Price Target | RYTM Stock News - GuruFocus
Obesity Market on Track for Major Expansion by 2034, According to DelveInsight | Rhythm Pharmaceuticals, Boehringer Ingelheim, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharm - Barchart.com
Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading Down 5.3%Time to Sell? - MarketBeat
SG Americas Securities LLC Buys 13,369 Shares of Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Rhythm Pharmaceuticals, Inc. $RYTM Holdings Lifted by Nisa Investment Advisors LLC - MarketBeat
Death Cross: Is Rhythm Pharmaceuticals Inc currently under institutional pressureJuly 2025 Summary & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Responsive Playbooks and the RYTM Inflection - Stock Traders Daily
Investment Report: Can Rhythm Pharmaceuticals Inc expand into new markets2025 Fundamental Recap & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A Biotech Gem with 38% Potential Upside - DirectorsTalk Interviews
What Rhythm Pharmaceuticals (RYTM)'s Strong IMCIVREE Revenue Beat Means For Shareholders - Sahm
Rhythm Pharmaceuticals stock price target raised to $130 from $120 at TD Cowen - Investing.com Canada
RYTM Stock Jumps 4% On Imcivree Revenue Growth: Firm Awaits Approval In Acquired Hypothalamic Obesity By March - Stocktwits
Needham Raises Price Target for Rhythm Pharmaceuticals (RYTM) to $148 | RYTM Stock News - GuruFocus
Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Expected to Rise, Needham & Company LLC Analyst Says - MarketBeat
Rhythm Pharmaceuticals (RYTM) Projects Strong Revenue Growth for 2025 - GuruFocus
Rhythm Pharmaceuticals announces preliminary, unaudited fourth quarter results - marketscreener.com
Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones - The Manila Times
PRN_FinancialWrapper - FinancialContent
How cyclical is Rhythm Pharmaceuticals Inc. (1RV) stock compared to rivalsJuly 2025 Reactions & High Win Rate Trade Tips - Улправда
How Rhythm Pharmaceuticals Inc. stock reacts to oil prices2025 Fundamental Recap & Community Verified Trade Alerts - ulpravda.ru
CEO Moves: Why Rhythm Pharmaceuticals Inc. (1RV) stock fits value portfolios2025 Biggest Moves & Advanced Swing Trade Entry Alerts - Улправда
Rhythm Pharmaceuticals, Inc. (RYTM): Analyst Consensus and Growth Potential Amidst a 32% Upside - DirectorsTalk Interviews
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Tops Revenue Estimates - MSN
Understanding the Setup: (RYTM) and Scalable Risk - Stock Traders Daily
Is Rhythm Pharmaceuticals Inc a good long term investmentEconomic Indicators Overview & No Fee. No Catch. Just Smart Investment Ideas - earlytimes.in
What Technical Indicators Signal for BLS E Next MonthCandlestick Trading Patterns & Identify Breakout Stocks - earlytimes.in
Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling - FinancialContent
Rhythm Pharmaceuticals (RYTM) stock falls today as biotech weakens; FDA decision stays in focus - ts2.tech
Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Down 3.3%Should You Sell? - MarketBeat
Rhythm advances lead asset into late-stage trial in Prader-Willi syndrome - MSN
Rhythm Pharma’s Rare-Obesity Drug Keeps Growth Rolling - Finimize
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Rhythm Pharmaceuticals (RYTM) Stock Analysis: Exploring a 26% Upside Potential in Biotech - DirectorsTalk Interviews
Does Rhythm Pharmaceuticals (NASDAQ:RYTM) Have A Healthy Balance Sheet? - 富途牛牛
Harbor Capital Advisors Inc. Has $3.76 Million Position in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Rhythm Pharmaceuticals (FRA:1RV) OCF Margin % : -51.90% (As of Sep. 2025) - GuruFocus
Rhythm Pharmaceuticals (FRA:1RV) EV-to-FCF : -62.60 (As of Dec. 25, 2025) - GuruFocus
Rhythm Pharmaceuticals (FRA:1RV) EV-to-OCF : -62.60 (As of Dec. 25, 2025) - GuruFocus
Why (RYTM) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
H.C. Wainwright raises Rhythm Pharmaceuticals stock price target on PWS trial data - Investing.com Canada
RYTM: HC Wainwright Raises Price Target for Rhythm Pharmaceutica - GuruFocus
Voya Investment Management LLC Has $22.38 Million Stake in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
HC Wainwright & Co. Maintains Rhythm Pharmaceuticals (RYTM) Buy Recommendation - Nasdaq
With Rhythm Pharmaceuticals Stock Surging, Have You Considered The Downside? - Trefis
What is the fair value estimate for Rhythm Pharmaceuticals Inc. (1RV) stock in 2025Earnings Growth Summary & Weekly High Return Stock Opportunities - Улправда
How Rhythm Pharmaceuticals Inc. stock performs in weak economy2025 Major Catalysts & Safe Capital Allocation Plans - Улправда
Assenagon Asset Management S.A. Sells 13,870 Shares of Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Rhythm Pharmaceuticals Inc Stock (RYTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rhythm Pharmaceuticals Inc Stock (RYTM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cramer Pamela J. | Chief Human Resources Officer |
Dec 11 '25 |
Sale |
111.00 |
3,350 |
371,850 |
20,814 |
5.17%
4.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):